Injection of anti-TLR9 antibody cannot efficiently block TLR9 activities in mice: a brief discussion about TLR9 location in cells

Abstract

Abstract:

In a paper published in this journal (No.1 Vol. 35, 2017) entitled The regulatory effect of dendritic cells on Th17 cell differentiation and function in mouse infected with Plasmodium yoelii, the authors stated in an experimental method that they used anti-TLR9 antibody to block dendritic cell function in mice. We do not think this method works out, because there have been accumulating data revealing that TLR9 is mainly an intracellular receptor, so injection of anti-TLR9 antibody cannot efficiently block TLR9 activities in vivo.

Key words: TLR9, Subcellular location, Anti-TLR9 antibody, Antagonist

CLC Number:

R392.1

Xiao LIU, Meng-meng LI, Feng QIAN. Injection of anti-TLR9 antibody cannot efficiently block TLR9 activities in mice: a brief discussion about TLR9 location in cells[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2017, 35(5): 485-488.

References 33

[1]	Yamada H, Gursel I, Takeshita F, et al. Effect of suppressive DNA on CpG-induced immune activation[J]. J Immunol, 2002, 169(10): 5590-5594.
[2]	Boehm O, Markowski P, van der Giet M, et al. In vivo TLR9 inhibition attenuates CpG-induced myocardial dysfunction[J]. Mediators Inflamm, 2013, 2013: 217297.
[3]	Zhang Y, Zhu X, Feng Y, et al. TLR4 and TLR9 signals stimulate protective immunity against blood-stage Plasmodium yoelii infection in mice[J]. Exp Parasitol, 2016, 170: 73-81.
[4]	胡坤, 王国玮, 王振海. HCV刺激小胶质细胞后TLR9蛋白的表达及其与MCP-1, TNF-α的关系[J]. 细胞与分子免疫学杂志, 2011, 27(10): 1083-1085.
[5]	杨雪姣, 刘万成, 祝元锋, 等. CpG-c41对TLR9信号通路的干扰作用及其机制探究[J]. 免疫学杂志, 2016, 32(12): 1024-1028.
[6]	周庆, 郝璐, 周泽强. 固有免疫系统Toll样受体的研究进展[J]. 生物学杂志, 2016, 33(3): 83-87.
[7]	李松, 车南颖, 张林波, 等. Toll样受体在结核病免疫应答中的作用[J]. 结核病与胸部肿瘤, 2010, 22(3): 218-222.
[8]	Zhou Y, Fang L, Peng L, et al. TLR9 and its signaling pathway in multiple sclerosis[J]. J Neurol Sci, 2017, 373: 95-99.
[9]	Chen JQ, Szodoray P, Zeher M.Toll-like receptor pathways in autoimmune diseases[J]. Clin Rev Allergy Immunol, 2016, 50(1): 1-17.
[10]	Bhattacharyya S, Varga J.Emerging roles of innate immune signaling and Toll-like receptors in fibrosis and systemic sclerosis[J]. Curr Rheumatol Rep, 2015, 17(1): 474.
[11]	Melisi D, Frizziero M, Tamburrino A, et al. Toll-like receptor 9 agonists for cancer therapy[J]. Biomedicines, 2014, 2(3): 211-228.
[12]	Aoshi T, Koyama S, Kobiyama K, et al. Innate and adaptive immune responses to viral infection and vaccination[J]. Curr Opin Virol, 2011, 1(4): 226-232.
[13]	Blasius AL, Beutler B.Intracellular Toll-like receptors[J]. Immunity, 2010, 32(3): 305-315.
[14]	Kim YM, Brinkmann MM, Paquet ME, et al. UNC93B1 delivers nucleotide-sensing Toll-like receptors to endolysosomes[J]. Nature, 2008, 452(7184): 234-238.
[15]	Lee BL, Moon JE, Shu JH, et al. UNC93B1 mediates differential trafficking of endosomal TLRs[J]. Elife, 2013, 2: e00291.
[16]	Ewald SE, Lee BL, Lau L, et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor[J]. Nature, 2008, 456(7222): 658-662.
[17]	Park B, Brinkmann MM, Spooner E, et al. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9[J]. Nat Immunol, 2008, 9(12): 1407-1414.
[18]	Sepulveda FE, Maschalidi S, Colisson R, et al. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells[J]. Immunity, 2009, 31(5): 737-348.
[19]	Ewald SE, Engel A, Lee J, et al. Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase[J]. J Exp Med, 2011, 208(4): 643-651.
[20]	Onji M, Kanno A, Saitoh S, et al. An essential role for the N-terminal fragment of Toll-like receptor 9 in DNA sensing[J]. Nat Commun, 2013, 4: 1949.
[21]	Mouchess ML, Arpaia N, Souza G, et al. Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation[J]. Immunity, 2011, 35(5): 721-732.
[22]	Babdor J, Descamps D, Adiko AC, et al. IRAP+ endosomes restrict TLR9 activation and signaling[J]. Nat Immunol, 2017, 18(5): 509-518.
[23]	Barton GM, Kagan JC, Medzhitov R.Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA[J]. Nat Immunol, 2006, 7(1): 49-56.
[24]	Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide[J]. Nature, 2007, 449(7162): 564-569.
[25]	吴翀, 丁国富, 周红. 抗人TLR9抗体对CpG寡核苷酸介导的人外周血单核细胞肿瘤坏死因子-α释放的影响[J]. 中国临床药理学与治疗学, 2006, 11(3): 324-327.
[26]	Guerrier T, Pochard P, Lahiri A, et al. TLR9 expressed on plasma membrane acts as a negative regulator of human B cell response[J]. J Autoimmun, 2014, 51: 23-29.
[27]	Rao DA, Gurish MF, Marshall JL, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis[J]. Nature, 2017, 542(7639): 110-114.
[28]	Liu Y, Liu A, Iikuni N, et al. Regulatory CD4+ T cells promote B cell anergy in murine lupus[J]. J Immunol, 2014, 192(9): 4069-4073.
[29]	Kohm AP, McMahon JS, Podojil JR, et al. Cutting edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+T regulatory cells[J]. J Immunol, 2006, 176(6): 3301-3305.
[30]	Zelenay S, Demengeot J.Comment on “Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+T regulatory cells”[J]. J Immunol, 2006, 177(4): 2036-2037; author reply 2037-2038.
[31]	Stephens LA, Anderton SM.Comment on “Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+T regulatory cells”[J]. J Immunol, 2006, 177(4): 2036; author reply 2037-2038.
[32]	Wang Z, Xiao L, Shi BY, et al. Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation[J]. Transpl Immunol, 2008, 19(1): 69-73.
[33]	Game DS, Hernandez-Fuentes MP, Lechler RI.Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro[J]. Am J Transplant, 2005, 5(3): 454-464.